From: Therapeutic nanoplatforms and delivery strategies for neurological disorders
 | Biomarker | Targeting strategy | Purpose | Examples | Refs. |
---|---|---|---|---|---|
GBM | MGMT methylation | Methylation-primer | Diagnosis | PCR-mMGMT | [149] |
PDGFRA mutation | PDGFRS-primer | Diagnosis | qPCR, qPCR-SSCP | [150] | |
PDGR inhibitor | GBM treatment | Sorafenib Matinib Tandutinib Dasatinib | [151] | ||
IDH mutation | Anti-R132H-IDH1 | Diagnosis | Immunohistochemistry | [152] | |
EGFR mutation | Anti-EGFRvIII | Diagnosis | Immunohistochemistry | [153] | |
EGFR inhibitor | GBM treatment | Erlotinib Nimotuzumab Gefitinib Cetuximab | [151] | ||
PD-1 | PD-1 inhibitor | GBM treatment | Nivolumab Pembrolizumab | [18] | |
CTLA-4 | CTLA-4 inhibitor | GBM treatment | Ipilimumab | [18] | |
AD | Aβ oligomer | Aβ aggregation inhibitor | AD treatment | Tramiprosate | [21] |
Aβ plaque | Aβ aggregation inhibitor | AD treatment | Colostrinin | [22] | |
Aβ PET ligand | PET imaging | CRANAD NIAD | [154] | ||
Tau | Tau aggregation inhibitor | AD treatment | Astemizole Lansoprazole | [23] | |
PD | DAT | Dopamine | PD treatment | L-DOPA | [27] |
Dopamine agonist | PD treatment | Bromocriptine | [28] | ||
D2/D3 radioligands | SPEC imaging PET imaging PET imaging | 123I-iodolisuride 11C-Raclopride 18F-Fallypride | [155] | ||
Cocaine derivatives | PET imaging PET imaging | 125I-RTI-55 76Br-PE2Br | [155] | ||
α-Synuclein | Anti-α-synuclein | Diagnosis | ELISA | [143] |